# Tumor-derived circulating DNA can induce senescence and SASP activation in mouse embryonic fibroblasts

**Authors:** Ekin Çelik, Ertan Kanbur

PMC · DOI: 10.1007/s10522-026-10400-9 · Biogerontology · 2026-02-05

## TL;DR

Tumor-derived DNA can trigger aging-like responses in normal cells, suggesting it may influence the environment around tumors.

## Contribution

This study shows that circulating tumor DNA can induce senescence and SASP in normal fibroblasts, a previously unexplored biological effect.

## Key findings

- ctDNA treatment caused a dose-dependent increase in senescence markers and SASP cytokines in MEFs.
- cfDNA had no significant effect on senescence or SASP compared to controls.
- ctDNA may act as a biologically active signal influencing stromal cell behavior in the tumor microenvironment.

## Abstract

Circulating tumor DNA (ctDNA), the tumor-originating fraction of cell-free DNA (cfDNA), is widely used as a biomarker for cancer detection and therapeutic monitoring; however, its direct biological impact on normal cells remains insufficiently understood. Since ctDNA contains tumor-derived molecular features, we hypothesized that it could serve as a signal that induces stress responses in healthy stromal cells. In this study, ctDNA and cfDNA were isolated from the conditioned media of B16-F10 melanoma and L929 fibroblast cultures, respectively, and applied to mouse embryonic fibroblasts (MEFs) at concentrations of 100 and 500 ng/mL for 24 h. Senescence was evaluated by SA-β-Gal staining alongside quantitative PCR analysis of senescence and SASP-associated genes, including p16, p21, p53, IL-6, and IL-1β. ctDNA treatment induced a pronounced, dose-dependent increase in senescence marker expression and SASP cytokine production, accompanied by elevated SA-β-Gal staining, whereas cfDNA treatment elicited no significant change compared to controls. These results indicate that ctDNA may act as a biologically active stimulus capable of eliciting senescence-like responses in normal fibroblasts, supporting the possibility that tumor-derived extracellular nucleic acids contribute to alterations in stromal behavior within the tumor microenvironment.

## Linked entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], TP53 (tumor protein p53) [NCBI Gene 7157], IL6 (interleukin 6) [NCBI Gene 3569], IL1B (interleukin 1 beta) [NCBI Gene 3553]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, Glb1 (galactosidase, beta 1) [NCBI Gene 12091] {aka Bge, Bgl, Bgl-e, Bgl-s, Bgl-t, Bgs}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, Cyp2b10 (cytochrome P450, family 2, subfamily b, polypeptide 10) [NCBI Gene 13088] {aka Cyp2b, Cyp2b20, p16}, Cdkn2a (cyclin dependent kinase inhibitor 2A) [NCBI Gene 12578] {aka ARF-INK4a, Arf, INK4a-ARF, Ink4a/Arf, MTS1, Pctr1}, Pum1 (pumilio RNA-binding family member 1) [NCBI Gene 80912] {aka Pumm, mKIAA0099}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}
- **Diseases:** melanoma (MESH:D008545), Tumor (MESH:D009369), cytotoxicity (MESH:D064420), infection (MESH:D007239), SASP (MESH:D008579), necrosis (MESH:D009336), HD (MESH:D006816), inflammation (MESH:D007249), viral infection (MESH:D014777), trauma (MESH:D014947)
- **Chemicals:** DMEM (-), DOX (MESH:D004317), PBS (MESH:D007854), CO2 (MESH:D002245), streptomycin (MESH:D013307), SA (MESH:D000077145), penicillin (MESH:D010406), reactive oxygen species (MESH:D017382)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** Cytion 305,157 — Homo sapiens (Human), Huntington's disease, Finite cell line (CVCL_L939), L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), CCL-1 — Mus musculus (Mouse), Undefined cell line type (CVCL_M023), MEF — Mus musculus (Mouse), Finite cell line (CVCL_9115), ATCC CRL-2991 — Homo sapiens (Human), Xeroderma pigmentosum, complementation group A, Finite cell line (CVCL_L768)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12876078/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12876078/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12876078/full.md

---
Source: https://tomesphere.com/paper/PMC12876078